Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Tenaya Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Tenaya Therapeutics, Inc.

TNYA

Tenaya Therapeutics, Inc.

About Tenaya Therapeutics, Inc.

Tenaya Therapeutics is a biotech company focused on discovering and developing gene therapies and precision medicines targeting the underlying causes of heart disease. Its pipeline includes gene therapies for genetic cardiomyopathies and small molecule inhibitors for heart failure with preserved ejection fraction (HFpEF). The company leverages genetic insights, advanced delivery technologies, and integrated manufacturing to create disease-modifying treatments for both rare and prevalent cardiac conditions.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Tenaya Therapeutics, Inc.

1
1
Tenaya Therapeutics, Inc. Tenaya Therapeutics Reports Q1 2026 Financial Results with Increased Collaboration Revenue

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Tenaya Therapeutics, Inc. Tenaya Therapeutics Reports $90.6M Net Loss and Business Update in 10-K Filing

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Tenaya Therapeutics, Inc. Tenaya Therapeutics Reports $20.3 Million Net Loss in Q3 2025, Reduces Operating Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Tenaya Therapeutics, Inc. Tenaya Therapeutics Reports $23.3 Million Net Loss in Q2 2025, Reduces Operating Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Tenaya Therapeutics, Inc. Tenaya Therapeutics Reports Q1 2025 Financial Results with $26.9M Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Tenaya Therapeutics, Inc. Tenaya Therapeutics Reports $111.1 Million Net Loss for 2024, Decreases Operating Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Tenaya Therapeutics, Inc. Tenaya Therapeutics Reports Financial Results, Decrease in Cash and Cash Equivalents, and Progress in Product Pipeline

Via official filing (AI summary) | over 1 year ago | 0 comments